Buying stocks on a dip can increase your odds of achieving higher returns, especially with quality stocks that could be due to rally. Below are three stocks trading near their 52-week lows that you might want to keep a close eye on.
1. Sunstone Hotel Investors
Sunstone Hotel Investors (SHO 1.20%) has struggled over the past year, falling 15% in 12 months. The REIT's troubles began late last year, when we saw the market as a whole struggle. And while Sunstone did begin to recover in 2019, its quarterly results have been inconsistent. In just the past four quarters, profits have been as low as $13 million and as high as $85.6 million.
Sunstone's focus is on hotels, so concerns about tougher economic times ahead and a corresponding decrease in demand might be weighing down Sunstone's share price. However, with many big-name brands in its portfolio like the Hilton and Hyatt, investors don't have much to worry about.
Sunstone could be a great buy today, trading within about 9% of its 52-week low.
IMAGE SOURCE: GETTY IMAGES.
2. Gilead Sciences
Gilead Sciences (GILD -0.51%) has struggled much like Sunstone has, failing to gain much traction this year and rising just 5% since January. What's surprising is that the biotech company is coming off a very strong Q2 that saw it not only beat expectations but raise its sales guidance for the remainder of 2019.
Gilead achieved lots of growth in its HIV medicines, and it still has a lot of potential to not only develop more products but expand into other parts of the world. In its most recent quarter, the bulk of the company's sales have come from the U.S. market (73%), with Europe accounting for about 18% and the remainder coming from other international markets.
Despite the positive results, investors have not shown a lot of excitement for the stock. While that's disappointing, it could be a great opportunity to buy the stock today, as it's trading at just 14 times earnings and within 10% of its 52-week low.
3. Fortive
Fortive Corporation (FTV 2.00%) has sent investors on a bit of a roller-coaster ride this year. When the stock came close to the $90 mark in April, 2019 was looking like a strong year for the company. Since then, however, Fortive has fallen short of sales expectations for Q1, and in Q2, management downgraded its outlook for the year.
Despite these setbacks, Fortive still has a lot of growth potential, especially in the infection-control market. There, the compounded annual growth rate is expected to be 6.5% until the end of 2022, when the market size is expected to reach more than $21 billion. And Fortive's recent acquisition of Advanced Sterilization Products puts the company in a good position to take advantage of that opportunity.
Currently, Fortive is trading within 7% of its 52-week low.
